OncoMatch/Clinical Trials/NCT05233397
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Is NCT05233397 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tocilizumab for adamantinomatous craniopharyngioma.
Treatment: Tocilizumab — ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Cannot have received: craniospinal irradiation
Lab requirements
Blood counts
Peripheral absolute neutrophil count (ANC) ≥1000/mm3; Platelet count ≥100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Hemoglobin >8 g/dL (may be transfused)
Kidney function
Creatinine clearance or radioisotope GFR > 70ml/min/1.73 m2 or age/gender-based serum creatinine thresholds
Liver function
Total bilirubin within normal institutional limits; AST (SGOT) ≤ 2.5 × institutional upper limit of normal; ALT (SGPT) ≤ 2.5 × institutional upper limit of normal
Adequate Bone Marrow Function... Adequate Renal Function... Adequate Liver Function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital Colorado · Aurora, Colorado
- Children's National Medical Center · Washington D.C., District of Columbia
- Nicklaus Children's Hospital · Miami, Florida
- Duke Children's Hospital · Durham, North Carolina
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify